Belgium · Delayed Price · Currency is EUR Ion Beam Applications Earnings Call Transcripts
Fiscal Year 2025
-
Record 2025 revenue and order intake drove profitability improvements, especially in proton therapy, with strong backlog and strategic investments supporting a positive outlook. Guidance for 2026 targets further EBIT growth and margin expansion, with gross margin and cash flow expected to improve as legacy contracts roll off.
-
Order intake and backlog remain strong, supporting confidence in meeting EBIT guidance of at least $25 million. New financing enhances balance sheet flexibility, while segment performance is robust despite some headwinds in Dosimetry.
-
Revenue surged 40% year-over-year to EUR 304.9 million, driven by strong backlog conversion and growth across all business units, though gross margin declined due to legacy projects. Guidance for 2025 is reaffirmed, with a minimum EUR 25 million rebit and positive outlook for proton therapy profitability.
-
Revised summary: Strong competitive positioning, innovation, and a capital-light strategy drive growth in industrial, clinical, and new venture segments. Financial guidance targets 5%-7% annual revenue growth and a 10% EBIT margin by 2028, with profitability from service scale, AI, and efficiency. Proton therapy adoption will accelerate with clinical evidence and global expansion.
Fiscal Year 2024
-
Record 2024 revenue and profitability driven by strong backlog and segment growth, with a positive outlook for 2025 and beyond. Strategic investments in R&D and new ventures support sustainable margins, while prudent guidance reflects market uncertainties.
-
Revenue grew 22% to €206.5M, with improved margins and a reduced net loss of €10.3M. Backlog conversion accelerated, especially in proton therapy and other accelerators, while the outlook remains strong with midterm EBIT margin targets reiterated.